Comparative Pharmacology
Head-to-head clinical analysis: NILOTINIB D TARTRATE versus PEMAZYRE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NILOTINIB D TARTRATE versus PEMAZYRE.
NILOTINIB D-TARTRATE vs PEMAZYRE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BCR-ABL tyrosine kinase inhibitor; binds to and inhibits the ATP-binding site of BCR-ABL, thereby inhibiting tyrosine kinase activity and downstream signaling pathways, leading to apoptosis in CML cells.
Selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4; binds to and inhibits FGFR kinase activity, leading to decreased tumor cell proliferation and angiogenesis.
400 mg orally twice daily, approximately 12 hours apart, with food.
13.5 mg orally once daily continuously until disease progression or unacceptable toxicity.
None Documented
None Documented
17 hours (terminal elimination half-life); supports once-daily dosing
Terminal elimination half-life is approximately 20 hours (range 14–32 h), supporting once-daily dosing with steady-state reached within 8 days.
Fecal (93%), renal (4%)
Primarily hepatobiliary excretion: 72% of the dose recovered in feces (mainly as unchanged drug and metabolites); renal excretion accounts for approximately 17% (less than 1% unchanged).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor